Company
We’re helping biopharma’s best teams change how medicine is made
130+
Companies
34
Countries
29
Connected scientific systems
Designed for scale
Enjamb is domain-specific AI for biopharma research and development. Our agents work across the systems behind a drug program, spanning discovery, preclinical, clinical operations, biometrics, regulatory, and quality, so context carries forward instead of stopping at every handoff. Teams at more than 130 biopharma companies in 34 countries use Enjamb to move programs faster without giving up scientific judgment. Enjamb is backed by Y Combinator, Founders Inc, and a group of top funds and angels.